Potomac Capital Management’s Gain Therapeutics GANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.61M Sell
930,000
-16,400
-2% -$29.9K 1.25% 23
2026
Q2
$1.92M Sell
946,400
-62,200
-6% -$115K 1.31% 20
2026
Q1
$1.96M Sell
1,008,600
-1,400
-0.1% -$3.05K 1.7% 15
2025
Q4
$3.25M Buy
+1,010,000
New +$2.7M 2.61% 11

Other funds holding GANX

Potomac Capital Management's GANX Position: Q3 2026 in Review

Potomac Capital Management reduced its Gain Therapeutics (GANX) stake by 1.7% in Q3 2026, selling an estimated $29.9K and leaving 930,000 shares worth $1.61M. The position accounts for 1.25% of the portfolio, ranked #23.

Potomac Capital Management first reported a position in GANX in Q4 2025 and has held it in 4 quarters since. The position peaked at $3.25M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

  • Potomac Capital Management held 930,000 shares of Gain Therapeutics worth $1.61M as of Q3 2026.
  • Potomac Capital Management sold 16,400 Gain Therapeutics shares in Q3 2026, an estimated $29.9K.
  • Gain Therapeutics made up 1.25% of Potomac Capital Management's portfolio in Q3 2026, its #23 holding.
  • Potomac Capital Management first reported a position in Gain Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Potomac Capital Management's Gain Therapeutics position peaked at $3.25M in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on Potomac Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.